Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.69 |
| ▸ | BACE1 | P56817 | 13/20 | 0.69 |
| ▸ | BCHE | P06276 | 12/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242759 | 1.00 | ACHE (0.69) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL242760 | 1.00 | ACHE (0.69) | ACHEBACE1BCHEDRD2DRD4 | |
| Bromide SCHEMBL2497824 | 0.98 | ACHE (0.68) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL2734633 | 0.91 | DRD2 (0.61) | ACHEBACE1BCHEDRD2DRD4 | |
| SCHEMBL2730825 | 0.90 | CYP1A2 (0.60) | ACHEBACE1BCHE | |
| SCHEMBL350928 | 0.90 | CYP1A2 (0.60) | ACHEBACE1BCHE | |
| SCHEMBL6128786 | 0.90 | CYP1A2 (0.60) | ACHEBACE1BCHE | |
| SCHEMBL360075 | 0.90 | ACHE (0.68) | ACHEBACE1BCHEDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL5862090 | 0.88 | ACHE (0.66) | ACHEBACE1BCHEDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL8055676 | 0.88 | ACHE (0.66) | ACHEBACE1BCHEDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111718250-B | Method for preparing R-citronellal | 万华化学集团股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-111718250-A | Method for preparing R-citronellal | 万华化学集团股份有限公司 | 2020-09-29 | — | — | CN | claimed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-111718250-B | Method for preparing R-citronellal | 万华化学集团股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| CN-111718250-A | Method for preparing R-citronellal | 万华化学集团股份有限公司 | 2020-09-29 | — | — | CN | disclosed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005080389-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | disclosed |
| US-20050080271-A1 | Peptidomimetic ligands for cellular receptors and ion channels | SEPRACOR INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050070589-A1 | Pyrazolyl inhibitors of 15- lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-31 | — | — | US | disclosed |
| US-20040259931-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004081005-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2001070684-A2 | PEPTIDOMIMETIC LIGANDS FOR CELLULAR RECEPTORS AND ION CHANNELS | SEPRACOR, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | ACHE 3462/4885BACE1 1032/4885BCHE 3611/4885 |
| US-20040259931-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | ACHE 2803/4885BACE1 4504/4885BCHE 1574/4885 |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | HTR4, HTR5A, HTR3C | ACHE 641/4885BACE1 3598/4885BCHE 2010/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | ACHE 3656/4885BACE1 1001/4885BCHE 3812/4885 |
| US-20050070589-A1 | Pyrazolyl inhibitors of 15- lipoxygenase | ALOX15, ALOX5, ALOX15B | ACHE 2188/4885BACE1 1377/4885BCHE 1537/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | ACHE 4531/4885BACE1 3907/4885BCHE 4372/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | ACHE 3656/4885BACE1 1001/4885BCHE 3812/4885 |
| US-20050080271-A1 | Peptidomimetic ligands for cellular receptors and ion channels | TRPV1, OPRL1, TRPV2 | ACHE 772/4885BACE1 2133/4885BCHE 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.